Nitroimidazole-based bioreductive compounds bearing a quinazoline or a naphthyridine chromophore

Anti-Cancer Drugs

Volumn 20, Issue 6, 2009, Pages 493-502

  Papadopoulou, Maria V ^a   Bloomer, William D ^a  

^a NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

Author keywords

Bioreductive agents; Naphthyridines; Nitroimidazoles; Quinazolines

Indexed keywords

4 [3 (2 NITRO 1 IMIDAZOLYL) PROPYLAMINOL] 1,5 NAPTHYRIDINE HYDROCHLORIDE; 4 [3 (2 NITRO 1 IMIDAZOLYL) PROPYLAMINOL] 2 METHYL QUINAZOLINE HYDROCHLORIDE; CISPLATIN; ETHIDIUM BROMIDE; MELPHALAN; NAPHTHYRIDINE DERIVATIVE; NITROIMIDAZOLE; QUINAZOLINE; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN V 79; CHROMATOPHORE; CLONOGENESIS; CLONOGENIC ASSAY; CYTOTOXICITY; DNA BINDING; DRUG STRUCTURE; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; RADIOSENSITIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; CELL LINE, TUMOR; CELL SURVIVAL; CRICETINAE; CRICETULUS; DRUG SYNERGISM; GAMMA RAYS; HUMANS; MOLECULAR STRUCTURE; NAPHTHYRIDINES; NITROIMIDAZOLES; QUINAZOLINES; RADIATION-SENSITIZING AGENTS;

EID: 67249115234     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32832cad9b     Document Type: Article

References (34)

1. Hall EJ, Giaccia AJ. Radiobiology for the radiologist. 6th ed. Philadelphia, PA: Lippincott, Wilkins & Watkins; 2005.
2. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects [Review]. J Natl Cancer Inst 2001; 93:266-276. (Pubitemid 32219813)
3. McKeown SR, Cowen RL, Williams KJ. Bioreductive drugs: from concept to clinic. Clin Oncol 2007; 19:427-442. (Pubitemid 46995614)
4. Denny WA, Wilson WR. Considerations for the design of nitrophenyl mustards as agents with selective toxicity for hypoxic tumour cells. J Med Chem 1986; 29:879-887. (Pubitemid 16068792)
5. Wilson WR, Anderson RF, Denny WA. Hypoxia-selective agents. 1. Relationship between structure, redox properties and hypoxia-selective cytotoxicity for 4-substituted derivatives of nitroacrines. J Med Chem 1989; 32:23-30. (Pubitemid 19025281)
6. Wilson WR, Denny WA. DNA-binding nitroheterocycles as hypoxia-selective cytotoxins. In: Dewey WC, Edington M, Fry RJM, Hall EJ, Whitmore GF, editors. Radiation research, a twentieth-radiation recentury perspective. San Diego: Academic Press; 1992. pp. 796-801.
7. Papadopoulou MV, Rosenzweig HS, Doddi M, Bloomer WD. 9-[3-(2-Nitro-1- imidazolyl)propylamino]-1,2,3,4-tetrahydroacridine hydrochloride. A novel DNA-affinic hypoxic cell cytotoxin and radiosensitizer. Comparison with NLA-1. Oncol Res 1994; 6:439-448.
8. Papadopoulou MV, Ji M, Rao MK, Bloomer WD. 9-[3-(2-Nitro-1-imidazolyl)- propylamino]cyclopenteno[b]quinoline hydrochloride (NLCPQ-1). A novel DNA-affinic bioreductive agent as cytotoxin and radiosensitizer. Oncol Res 1996; 8:425-434. (Pubitemid 27173040)
9. Papadopoulou MV, Bloomer WD. NLCQ-1 (NSC 709257): exploiting hypoxia with a weak DNA-intercalating bioreductive drug [Review]. Clin Cancer Res 2003; 9:5714-5720. (Pubitemid 37499495)
10. Papadopoulou MV, Rosenzweig HS, Bloomer WD. Synthesis of novel 2-nitroimidazole-tethered tricyclic quinolines, bearing a second heteroatom, and their in vitro evaluation as hypoxia-selective cytotoxins and radiosensitizers. Bioorg Med Chem Lett 2004; 14:1519-1522. (Pubitemid 38299442)
11. Papadopoulou MV, Bloomer WD, Taylor AP, Hernandez M, Blumenthal RD, Hollingshead MG. Advantage in combining NLCQ-1 (NSC 709257) with radiation in treatment of human head and neck xenografts. Radiat Res 2007; 168:65-71. (Pubitemid 351292926)
12. Blumenthal RD, Taylor A, Osorio L, Ochakovskaya R, Raleigh J, Papadopoulou MV, et al. Optimizing the use of combined radio-immunotherapy and hypoxic cytotoxin therapy as a function of tumor hypoxia. Int J Cancer 2001; 94:564-571. (Pubitemid 32979550)
13. Papadopoulou MV, Ji M, Bloomer WD. Schedule-dependent potentiation of chemotherapeutic drugs by the bioreductive compounds NLCQ-1 and Tirapazamine against EMT6 tumors in mice. Cancer Chemther Pharmacol 2001; 48:160-168. (Pubitemid 32710228)
14. Scarborough HC, Lawers BC, Mikielli JL, Compton JL, Pyrrolidines. VI. Synthesis of 4-(1-substituted 3-pyrrolidinylmethylamino)- and 4-(1-substituted 3-pyrrolidinylmethoxy)-quinazolines. J Org Chem 1962; 27:957.
15. Adams JT, Bradsher CK, Breslow DS, Amore ST, Hauser CR. Synthesis of antimalarials. VI. Synthesis of certain 1,5- and 1,8-naphthyridine derivatives. J Am Chem Soc 1946; 68:1317-1319.
16. Morgan AP, Lee JS, Pulleyblank DE, Murray NL, Evans DH. Review: ethidium fluorescence assays. Part 1. Physicochemical studies. Nucleic Acids Res 1979; 7:547-569. (Pubitemid 10246793)
17. Robbie MA, Baguley BC, Denny WA, Gavin JB, Wilson WR. Mechanism of resistance of noncycling mammalian cells to 4′-(9-acridylamino) methanesulfon-m-anisidine: comparison of uptake, metabolism, and DNA breakage in log and plateau-phase Chinese hamster fibroblast cell cultures. Cancer Res 1988; 48:310-319. (Pubitemid 18045763)
18. Brown JM, Lemmon MJ. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res 1990; 50:7745-7749.
19. Papadopoulou MV, Ji M, Rao MK, Bloomer WD. 4-[3-(2-Nitro-1-imidazolyl)- propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive compound as a hypoxia-selective cytotoxin. Oncol Res 2000; 12:185-192.
20. Goossens J-F, Bouey-Bencteux E, Houssin R, Henichart J-P, Colson P, Houssier C, et al. DNA interaction of the tyrosine protein kinase inhibitor PD153035 and its N-methyl analogue. Biochem 2001; 40:4663-4671. (Pubitemid 32374654)
21. Grunt TW, Tomek K, Wagner R, Puckmair K, Kainz B, Runzler D, et al. Upregulation of retinoic acid receptor-b by the epidermal growth factor-receptor inhibitor PD153035 is not mediated by blockade of ErbB pathways. J Cell Physiol 2007; 211:803-815. (Pubitemid 46683048)
22. Wilson WR, van Zijl P, Denny WA. Bis-bioreductive agents as hypoxia-selective cytotoxins: nitracrine N-oxide. Int J Radiat Oncol Biol Phys 1992; 22:693-697.
23. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3:721-732. (Pubitemid 37328811)
24. Chittezhath M, Deep G, Singh RP, Agarwal C, Agarwal R. Silibinin inhibits cytokine-induced signaling cascades and down-regulates inducible nitric oxide synthase in human lung carcinoma A549 cells. Mol Cancer Ther 2008; 7:1817-1826.
25. Yamaguchi H, Kidachi Y, Umetsu H, Ryoyama K. Hypoxia enhances gene expression of inducible nitric oxide synthase and matrix metalloproteinase-9 in ras/myc-transformed serum-free mouse embryo cells under simulated inflammatory and infectious conditions. Cell Biol Int 2008; 32:940-949.
26. Fitzpatrick B, Telfer BL, Babur M, Bloomer WD, Papadopoulou MV, Cowen RL, et al. Inducible nitric oxide synthase (iNOS) as a radiosensitizer and potentiator of bioreductive drugs in vivo. Proc Am Assoc Cancer Res Annu Meet 2008; 49: abstract 415.
27. Goldstein BP, Vidal-Plana RR, Cavalleri B, Zerilli L, Carniti G, Silvestri LG. The mechanism of action of nitro-heterocyclic antimicrobial drugs. Metabolic activation by microorganisms. J Gen Microbiol 1977; 100:283-298.
28. Papadopoulou MV, Ji M, Bloomer WD. THNLA-1: a DNA-targeted bioreductive agent as chemosensitizer in vitro and in vivo. In Vivo 1996; 10:49-58. (Pubitemid 126700396)
29. Papadopoulou MV, Ji M, Rao MK, Bloomer WD. 9-[3-(2-Nitro-1-imidazolyl)- propylamino]-cyclopenteno[b]quinoline hydrochloride (NLCPQ-1). A novel DNA-affinic bioreductive agent as chemosensitizer. I. Oncol Res 1997; 9:249-257. (Pubitemid 127825977)
30. Papadopoulou MV, Ji X, Bloomer WD. Potentiation of alkylating agents by NLCQ-1 or TPZ in vitro and in vivo. J Exp Ther Oncol 2006; 5:261-272. (Pubitemid 44497001)
31. Papadopoulou MV, Ji M, Bloomer WD. NLCQ-1, a novel hypoxic cytotoxin: potentiation of melphalan, cisDDP and cyclophosphamide in vivo. Int J Radiat Oncol Biol Phys 1998; 42:775-779. (Pubitemid 28559415)
32. Taylor YC, Bump EA, Brown JM. Studies on the mechanisms of chemosensitization by misonidazole in vitro. Int J Radiat Oncol Biol Phys 1982; 8:705-708. (Pubitemid 12090613)
33. Kovacs MS, Hocking DJ, Evans JW, Siim BG, Wouters BG, Brown JM. Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin. Br J Cancer 1999; 80:1245-1251. (Pubitemid 29264086)
34. Papadopoulou MV, Bloomer WD. DNA repair mechanisms are involved in the hypoxia-dependent toxicity of NLCQ-1 (NSC 709257) and its synergistic interaction with alkylating agents. In Vivo 2007; 21:175-180. (Pubitemid 46534269)